The Journal of Faculty of Pharmacy of Ankara University is an international medium, an open access, peer-reviewed journal for the publication of original research reports, reviews and short communications in English or Turkish on relevant developments in pharmaceutical sciences., Proceeding of scientific meetings may be published as special issues of supplements to the journal. Additionally, it contains previous and forthcoming national and international scientific meetings with social activities in pharmaceutical areas.
Research Article
Year 2018,
Volume: 42 Issue: 2, 23 - 31, 31.05.2018
Abstract
Amaç: Proton Pompası İnhibitörleri (PPİ) Peptik Ülser, Gastroözofagial Reflü, Gastrit ve diğer Sindirim sistemi asit sekresyon hastalıklarında kullanılan güçlü ilaçlardır. Bu çalışmada bu grup ilaçların Türkiye’de 2006-2011 yıllarına göre tüketimleri incelenerek Farmakoekonomik açıdan maliyet analizi yapılacaktır.
Gereç ve Yöntem: PPİ ilaçları hakkında karşılaştırmaların yapıldığı son yıllarda yayınlanmış çalışmaların sonuçları ve Intercontinental Marketing Services – Health (IMS/Health) den alınan 2006-2011 yılları arasındaki tüketim verileri üzerinden analiz gerçekleştirilmiştir.
Sonuç ve Tartışma: Tüm PPİ’lerin 2006 yılından 2011 yılına kadar kutu bazında satışları omeprazol haricinde yüksek oranlarda artmıştır. Diğer PPİ’lere göre daha düşük maliyetli olan omeprazol’ün hekimler tarafından tercih edilmediği görülmüştür. Karşılaştırmalı analizlerde PPİ’lerinin etkinlik açısından istatistiksel olarak anlamlı farklarının olmadığı tespit edilmiştir. Tartışma:Tedavide anlamlı bir farkı olmayan PPİ’lerin tüketiminde daha pahalı ilaçlara bir reçete göçü söz konusudur. Geri ödeme bütçeleri için daha maliyet-etkili ilaçların tüketilmesi gerekmektedir. Bu nedenle gerekli endikasyonlarda omeprazol’ün tüketilmesi teşvik edilmeli veya diğer grup ilaçların omeprazol maliyetinden geri ödemesinin yapılması gerekmektedir.
References
- Klotz, U. (2000). Pharmacokinetic considerations in the eradication of helicobacter pylori. Clinical Pharmacokinetics Journal, 38, 243–270
- Esplugues, J.V., Martí-Cabrera, M., Ponce, J. (2006) Safety of protonpump inhibitors. Medicina Clinica, 127, 790–795
- Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K., Ishizaki, T. (2004). Pharmacogenomics of proton pump inhibitors. Pharmacogenomics, 2, 181–202
- Klotz, U. (2006). Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a specialproblem. International Journal of Clinical Pharmacology and Therapeutics, 44, 297–302
- Aydın, D. (2009). Dört farklı proton pompa inhibitörünün gastrik asit salınımı üzerindeki etkinliklerinin karşılaştırılması. İç Hastalıkları Anabilim Dalı Uzmanlık Tezi. Kocaeli Üniversitesi Tıp Fakultesi
- Lightdale, C. J., Schmitt, C., Hwang, C., Hamelin, B. (2006). A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Digestive Diseases Sciences, 51(5), 852–857
- Schmitt, C., Lightdale, C. J., Hwang, C., Hamelin, B. (2006). A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (40 mg) and standard-dose omeprazole (20 mg) for the treatment of erosive esophagitis. Digestive Diseases Sciences, 51(5), 844–850.
- Zheng, R.N. (2009). Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World Journal of Gastroenterology, 15(8), 990-999
- Çetinkaya, Z.A., Sezikli, M., (2011). Comparison of the efficacy of proton pump inhibitors used in the eradication of Helicobacter pylori, Akademik Gastroenteroloji Dergisi, 10 (1), 01-04
- Aladağ, M. (1999). Helicobacter pylori eradikasyonunda proton pompa inhibitörlerinin etkinliklerinin (lansoprazol ve omeprazol) kıyaslanması. Journal of Inonu University Medical Faculty, Vol 6, No 2
- Johnson, D.A., Stacy, T., Ryan, M., Wootton, T., Willis, J., Hornbuckle, K., Brooks, W., Doviak, M. (2005). A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro- oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 22, 129–134
- Zhao, F. (2008). Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump ınhibitor-based triple therapy for helicobacter pylori eradication: A Meta-Analysis, Helicobacter, Volume 13, Issue 6, 532–541
- IMS/Health Turkey 2006-2011.
Year 2018,
Volume: 42 Issue: 2, 23 - 31, 31.05.2018
Abstract
Objective: Proton Pump Inhibitors are safe and powerful drugs which used in PU, GERD, gastiritis and other digestive system acid secretion diseases. In this study, comparative analysis of PPI drugs and consumption of products by years in Turkey examined to make a pre-paharmacoecomic analysis.
Material and Method: A analysis of by using the results of the comparative analysis published in recent years about PPI drugs and the consumption data of PPI drug, which were taken from Intercontinental Marketing Services – Health (IMSHealth) within years 2006-2011.
Result and Discussion: All sales of PPI drugs were increased highly in years 2006-2011 except omeprazole. The consumption of products shows that omeprazole, which had low cost than other drugs not preferred by physicians. In comparative analyzes it was determined that there was no statistically significant difference in efficiency of PPIs. There is a prescription migration to more expensive medicines for the consumption of PPIs, which have no significant difference in treatment. More cost-effective drugs need to be consumed for reimbursement budgets. For this reason, omeprazole consumption should be encouraged in necessary indications, or it is necessary to repay the cost of the other group of drugs from omeprazole’s cost.
References
- Klotz, U. (2000). Pharmacokinetic considerations in the eradication of helicobacter pylori. Clinical Pharmacokinetics Journal, 38, 243–270
- Esplugues, J.V., Martí-Cabrera, M., Ponce, J. (2006) Safety of protonpump inhibitors. Medicina Clinica, 127, 790–795
- Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K., Ishizaki, T. (2004). Pharmacogenomics of proton pump inhibitors. Pharmacogenomics, 2, 181–202
- Klotz, U. (2006). Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a specialproblem. International Journal of Clinical Pharmacology and Therapeutics, 44, 297–302
- Aydın, D. (2009). Dört farklı proton pompa inhibitörünün gastrik asit salınımı üzerindeki etkinliklerinin karşılaştırılması. İç Hastalıkları Anabilim Dalı Uzmanlık Tezi. Kocaeli Üniversitesi Tıp Fakultesi
- Lightdale, C. J., Schmitt, C., Hwang, C., Hamelin, B. (2006). A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Digestive Diseases Sciences, 51(5), 852–857
- Schmitt, C., Lightdale, C. J., Hwang, C., Hamelin, B. (2006). A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (40 mg) and standard-dose omeprazole (20 mg) for the treatment of erosive esophagitis. Digestive Diseases Sciences, 51(5), 844–850.
- Zheng, R.N. (2009). Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World Journal of Gastroenterology, 15(8), 990-999
- Çetinkaya, Z.A., Sezikli, M., (2011). Comparison of the efficacy of proton pump inhibitors used in the eradication of Helicobacter pylori, Akademik Gastroenteroloji Dergisi, 10 (1), 01-04
- Aladağ, M. (1999). Helicobacter pylori eradikasyonunda proton pompa inhibitörlerinin etkinliklerinin (lansoprazol ve omeprazol) kıyaslanması. Journal of Inonu University Medical Faculty, Vol 6, No 2
- Johnson, D.A., Stacy, T., Ryan, M., Wootton, T., Willis, J., Hornbuckle, K., Brooks, W., Doviak, M. (2005). A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro- oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 22, 129–134
- Zhao, F. (2008). Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump ınhibitor-based triple therapy for helicobacter pylori eradication: A Meta-Analysis, Helicobacter, Volume 13, Issue 6, 532–541
- IMS/Health Turkey 2006-2011.
There are 13 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Research Article |
| Authors | |
| Publication Date | May 31, 2018 |
| Submission Date | July 5, 2018 |
| Published in Issue | Year 2018 Volume: 42 Issue: 2 |